The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression).

Cell cycle (Georgetown, Tex.)

Volumn 1, Issue 1, 2002, Pages 90-96

  Sax, Joanna K ^a   Dash, Bipin C ^a   Hong, Rui ^a   Dicker, David T ^a   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BUTYROPHENONE DERIVATIVE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYSTEINE PROTEINASE INHIBITOR; DRUG DERIVATIVE; LACTACYSTIN; MESSENGER RNA; PROTEIN P53;

ARTICLE; BINDING SITE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; DNA DAMAGE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; TIME;

ACETYLCYSTEINE; BINDING SITES; BUTYROPHENONES; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; CYSTEINE PROTEINASE INHIBITORS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE; GENE EXPRESSION; HUMANS; RNA, MESSENGER; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036044835     PISSN: 15384101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)